A Phase 2/3 interventional study of VX-147 and Placebo in Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated. Active, not recruiting at 314 sites in 13 countries. Open to participants aged 10 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Part A:
Part B:
- Completion of Treatment Period in Part A and no permanent discontinuation of study drug.
Key Exclusion Criteria:
Part A:
Part B:
Other protocol defined Inclusion/Exclusion criteria will apply.
Participants will be randomized to receive different doses of VX-147. Participants will receive the selected dose of VX-147 for atleast 96 weeks.
Drug: VX-147
Participants will receive placebo matched to VX-147.
Drug: Placebo
Participants who complete Part A will receive VX-147 for an additional 96 weeks.
Drug: VX-147
Tablets for oral administration.
Tablets for oral administration.
Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)
Time frame: From Baseline to Week 48
Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim Analysis
Time frame: From Baseline Through >= Week 48
Part A: eGFR Slope Assessed at Final Analysis
Time frame: From Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 Through Study Completion (Approximately 2 Years After the Last Participant Enrolls)
Part A: Maximum Plasma Concentration (Cmax) of VX-147
Time frame: Day 1 and Week 40
Part A: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-147
Time frame: Day 1 and Week 40
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-147
Time frame: Day 1 up to Week 40
Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4
Time frame: Day 1 and Week 48
Part B: Percent Change From Baseline in UPCR Over Time
Time frame: From Baseline Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)
Part B: eGFR Slope Assessment
Time frame: Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)
Showing the first 100 of 314 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Jun 2028, 74 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inaxaplin
Vertex Pharmaceuticals Incorporated →